2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

49. Nelson RM, Botkin JR, Kodish ED, et al. Ethical issues with genetic
testing in pediatrics. Pediatrics. 2001;107:1451-1455.
50. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and
therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658-5671.
51. GeneReviews. www.genetests.org. Accessed March 23, 2012.
52. Debaun MR. Screening protocol for Beckwith-Wiedemann syndrome.
http://www.beckwith-wiedemann.info/protocol.html. Accessed February 6,
2012.
53. Durno CA, Aronson M, Tabori U, et al. Oncologic surveillance for
subjects with biallelic mismatch repair gene mutations: 10-year follow-up of a
kindred. Pediatr Blood Cancer. Epub 2011 Dec 16.
54. Timmers HJ, Gimenez-Roqueplo AP, Mannelli M, et al. Clinical aspects
of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer.
2009;16:391-400.
584
KNAPKE ET AL
55. National Cancer Institute. Retinoblastoma treatment (Physician Data
Query). http://www.cancer.gov/cancertopics/pdq/treatment/retinoblastoma/
HealthProfessional.Accessed January 30, 2012.
56. National Comprehensive Cancer Network. Genetic/familial high-risk
assessment: breast and ovarian. NCCN Clinical Practice Guidelines in
Oncology. Version 1.2011. www.nccn.org. Accessed February 6, 2012.
57. VHL Family Alliance. Suggested protocol for screening. www.vhl.org.
Accessed February 6, 2012.
58. Scott RH, Walker L, Olsen OE, et al. Surveillance for Wilms tumor in
at-risk children: pragmatic recommendations for best practice. Arch Dis
Child. 2006;91:995-999.
59. Choyke PL, Siegel MJ, Craft AW, et al. Screening for Wilms tumor in
children with Beckwith-Wiedemann syndrome or idiopathic hemihypertrophy.
Med Pediatr Oncol. 1999;32:196-200.